Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.
Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH.
J Am Coll Cardiol. 2021 Dec 21;78(25):2505-2517. doi: 10.1016/j.jacc.2021.07.065.
Laser-Assisted Drug Delivery.
Alegre-Sánchez A, Jiménez-Gómez N, Boixeda P.
Actas Dermosifiliogr (Engl Ed). 2018 Dec;109(10):858-867. doi: 10.1016/j.ad.2018.07.008. Epub 2018 Sep 25.
SENSe: Study of the Effectiveness of Neurorehabilitation on Sensation: a randomized controlled trial.
Carey L, Macdonell R, Matyas TA.
Neurorehabil Neural Repair. 2011 May;25(4):304-13. doi: 10.1177/1545968310397705. Epub 2011 Feb 24.
Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy.
Sheikh FH, Habib G, Tang WHW, Gillmore JD, Egolum UO, Longhi S, Chen C, Aldinc E, Fontana M.
J Am Coll Cardiol. 2025 May 27;85(20):1943-1955. doi: 10.1016/j.jacc.2025.03.454. Epub 2025 Mar 17.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group.
N Engl J Med. 2001 Sep 20;345(12):851-60. doi: 10.1056/NEJMoa011303.
Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.
von Haehling S, Doehner W, Evertz R, Garfias-Veitl T, Derad C, Diek M, Karakas M, Birkemeyer R, Fillippatos G, Lainscak M, Butler J, Ponikowski P, Böhm M, Friede T, Anker SD.
Eur Heart J. 2024 Oct 5;45(37):3789-3800. doi: 10.1093/eurheartj/ehae479.
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E; NHLBI Heart Failure Clinical Research Network.
JAMA. 2017 May 16;317(19):1958-1966. doi: 10.1001/jama.2017.5427.
Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.
Borlaug BA, Zile MR, Kramer CM, Ye W, Ou Y, Hurt K, Murakami M, Packer M; SUMMIT Trial Study Group.
J Am Coll Cardiol. 2025 Jul 29;86(4):242-255. doi: 10.1016/j.jacc.2025.04.059.
Abatacept for the treatment of myositis-associated interstitial lung disease.
Aggarwal R, Pongtarakulpanit N, Sullivan DI, Moghadam-Kia S, Bae SS, Wilkerson J, Saygin D, Marder G, Venuturupalli S, Dellaripa PF, Danoff SK, Doyle T, Hunninghake GM, Lee JS, Fischer A, Falk J, Johnson C, Koontz D, Ascherman DP, Oddis CV.
Rheumatology (Oxford). 2025 Dec 1;64(SI):SI156-SI168. doi: 10.1093/rheumatology/keaf218.
Respirator weaning.
Hodgkin JE, Bowser MA, Burton GG.
Crit Care Med. 1974 Mar-Apr;2(2):96-102. doi: 10.1097/00003246-197403000-00009.
